The “Wegovy” brand slimming syringe is sold at the Achat pharmacy in Mitte. The slimming syringe “Wogovy” has been available in Germany for a year.
Jens Kalaene | Image Alliance | Getty images
Novo Nordisk Monday said he is finishing his collaboration with Hims and hers Due to the concerns about sales and promotion of the Telesalud company and the promotion of cheaper imitations of the medicine to lose weight.
HIMS & HERS shares closed more than 34% lower on Monday, while Novo Nordisk actions closed more than 5% lower.
Novo Nordisk in April said he would offer Wagovy through several Telesalud companies such as Hims & Hers to expand access to great success injection now that it is no longer scarce in the United States.
The end of the damn shortage meant that aggravating pharmacies were legally restricted to make and sell cheaper and unveiled versions of the medication for May 22, with rare exceptions. Telesalud's companies have said that patients may still need customized compound versions of WOGOVY in situations in which it is medically necessary.
But Novo Nordisk said on Monday that Hims & Hers “has not adhered to the law that prohibits massive sales of composite drugs” under the “false appearance” of customization. The drug manufacturer also accused him and hers of “misleading” marketing that is putting patient safety at risk.
“We expected the efforts to aggravate customization will decrease over time. When we didn't see that, we had to make a decision on behalf of the patients,” Dave Moore, executive vice president of US Navo Nordisk, told CNBC. “We have been firm all the time that patient safety is our main approach.”
“Our expectation was that [Hims & Hers’] The commercial approach would be transferred to real, safe and approved medications, “he said. Moore said that Novo Nordisk will not incur any rate for finishing the collaboration, since it was established through a third party that manages the pharmacy in direct line to drug use
In a statement about X, the CEO of Hims & Hers, Andrew Dudum, said the company is “disappointed to see Novo Nordisk Management deceiving the public.”
Dudum said that in recent weeks, Novo Nordisk's commercial team “has been pressed more and more to control clinical standards and direct patients to Wagovy, regardless of whether it was clinically better for patients.” He added that HIMS and his plays a role in the protection of suppliers and patients to control individual treatment decisions, and “will not compromise the integrity of our platform to appease a third party or preserve a collaboration.”
He said Hims and hers will continue to offer several treatments, including Wagovy, to allow suppliers to meet the individual needs of patients.
In a note on Monday, Citi analyst Daniel Grosslight said that the end of the collaboration increases the “legal risk” substantially.
During the shortage of food and medicines administration, pharmacists can legally make compound versions of brand medications. Case may also occur when it is medically necessary for a patient, such as when a pill cannot be swallowed or are allergic to a specific ingredient in a brand medication.
But drug manufacturers and some health experts have rejected the practice, in large part because the FDA does not approve composite drugs.
Novo Nordisk said he will continue offering the brand version of Wegovy organizations through Telesalud that “share our commitment to safe and effective medical treatment for patients living with chronic diseases.”
Moore said Novo Nordisk has seen several other pharmacies of mass composition reduce or stop doing and selling morons. He added that the company will “participate in the legal front” and with the FDA to ensure that the illegal compound decreases.
In a statement on Monday, Novo Nordisk said he conducted an investigation that found that the active ingredients used in the imbeciles of the imitations sold by Telesalud companies and composite pharmacies are manufactured by foreign suppliers in China. The drug manufacturer also cited a report by Brookings Institution in April, which found that a large part of those Chinese suppliers were never inspected by the FDA, and many who were inspected had drug guarantee rapes.
“These medications that come to our country from fountains around the world are not even approved in those countries that originated, and it is a problem,” said Moore.
